Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report

A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently di...

Descripción completa

Detalles Bibliográficos
Autores principales: Edahiro, Ryuya, Ishijima, Mikako, Kurebe, Hiroyuki, Nishida, Kohei, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500988/
https://www.ncbi.nlm.nih.gov/pubmed/30964601
http://dx.doi.org/10.1111/1759-7714.13065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500988/
https://www.ncbi.nlm.nih.gov/pubmed/30964601
http://dx.doi.org/10.1111/1759-7714.13065

Ejemplares similares